Physician profile
Nirali Patel
NPI 1639401169
$1,787.01
in general payments reported to CMS, 2019-2025
11 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.81 · 2021: $118 · 2022: $197 · 2023: $543 · 2024: $428 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,426.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $476.02 | 2019-2025 | Cequa, Winlevi, Ilumya |
| Tarsus Pharmaceuticals, INC. | $298.10 | 2024-2025 | Xdemvy |
| Abbvie INC. | $253.26 | 2024-2025 | |
| Oyster Point Pharma, INC. | $245.59 | 2022-2024 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $137.72 | 2021-2023 | |
| Alcon Vision LLC | $93.03 | 2023-2025 | Eysuvis, Tryptyr, Rocklatan |
| Coopervision INC. | $71.83 | 2023-2024 | Myday Contact Lens |
| Dompe US, INC. | $64.47 | 2023-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $57.11 | 2024-2025 | Miebo, Xiidra |
| Allergan, INC. | $45.55 | 2021-2022 | |
| Carl Zeiss Meditec USA, INC. | $44.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirali Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.